AstraZeneca forms drug delivery partnership; Aytu BioScience completes $5M financing round;

> AstraZeneca ($AZN) signed a licensing agreement with Starpharma enabling the development and commercialization of targets using the Australian company's drug delivery technology. AstraZeneca will pay Starpharma $2 million up front, and potentially more than $100 million in milestone payments based on product development, launch and sales levels. More

> Aytu BioScience announced that it has completed its private placement convertible note financing, raising $5.175 million in support of its orally disintegrating tablet that's formulated to treat premature ejaculation. More

Suggested Articles

Kala Pharma's Eysuvis on Tuesday became the first and only corticosteroid approved to treat short-term signs and symptoms of dry eye disease.

Xeris scored an FDA fast track designation for its diazepam formulation, delivered via autoinjector, to treat acute repetitive seizures.

Armed with microrobots and magnetic fields, Pursue scientists are looking to the future of targeted drug delivery, starting with the colon.